Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.11/Share
November 13, 2019 4:18 PM ESTCyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.11), versus ($0.18) reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More